Anete C. Ferraz
C.p. 19 031, 81 531-990
Curitiba, PR, Brazil
Curitiba, PR, Brazil
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Fish-oil supplementation decreases Indoleamine-2,3-Dioxygenase expression and increases hippocampal serotonin levels in the LPS depression model.
Journal: Behavioural brain research
Published: October 18, 2019
Fish oil supplementation reverses behavioral and neurochemical alterations induced by swimming exercise in rats.
Journal: Physiology & behavior
Published: December 13, 2017
Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase.
Journal: Nutritional neuroscience
Published: February 22, 2017
ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease.
Journal: Molecular neurobiology
Published: February 22, 2016
Maternal Omega-3 Supplement Improves Dopaminergic System in Pre- and Postnatal Inflammation-Induced Neurotoxicity in Parkinson's Disease Model.
Journal: Molecular neurobiology
Published: November 06, 2015
Indoleamine-2,3-Dioxygenase/Kynurenine Pathway as a Potential Pharmacological Target to Treat Depression Associated with Diabetes.
Journal: Molecular neurobiology
Published: July 10, 2015
REM sleep deprivation reverses neurochemical and other depressive-like alterations induced by olfactory bulbectomy.
Journal: Molecular neurobiology
Published: February 05, 2014
Fish oil improves anxiety-like, depressive-like and cognitive behaviors in olfactory bulbectomised rats.
Journal: The European journal of neuroscience
Published: June 14, 2013
Dopaminergic D2 receptor is a key player in the substantia nigra pars compacta neuronal activation mediated by REM sleep deprivation.
Journal: Neuropharmacology
Published: April 30, 2013
Multiple intranigral unilateral LPS infusion protocol generates a persistent cognitive impairment without cumulative dopaminergic impairment.
Journal: CNS & neurological disorders drug targets
Published: February 08, 2013
Last Updated: 09/26/2026